Several problems about the stereotactic body radiation therapy for lung cancer

doi:10.3760/cma.j.issn.1673-422X.2018.03.011

Abstract

Abstract: As the first treatment of choice for medically inoperable patients with early stage nonsmall cell lung cancer, it is demonstrated that the therapeutic outcome of stereotactic body radiation therapy (SBRT) is similar to that of surgery, but the data is mainly from nonrandomized controls and retrospective studies. More cases of randomized prospective clinical trials are needed to confirm the conclusions. The biologically effective dose >100Gy is associated with improved local control and overall survival, and the small tumor volume is correlated with higher local control rate.

Key words: Carcinoma, non-smallcell lung, Stereotactic body radiation therapy

Su Chuanghuang, Li Derui. Several problems about the stereotactic body radiation therapy for lung cancer[J]. Journal of International Oncology, 2018, 45(3): 176-179.

References

［1］ Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage Ⅰ nonsmallcell lung cancer: a pooled analysis of two randomised trials［J］. Lancet Oncol, 2015, 16(6): 630-637. DOI: 10.1016/S1470-2045(15)70168-3. ［2］ Shibamoto Y, Hashizume C, Baba F, et al. Stereotactic body radiotherapy using a radiobiologybased regimen for stage Ⅰ nonsmall cell lung cancer［J］. 2012, 118(8): 2078-2084. DOI: 10.1002/cncr.26470. ［3］ Shirvani SM, Jiang J, Chang JY, et al. Comparative effectiveness of 5 treatment strategies for earlystage nonsmall cell lung cancer in the elderly［J］. Int J Radiat Oncol Biol Phys, 2012, 84(5): 1060-1070. DOI: 10.1016/j.ijrobp.2012.07.2354. ［4］ Miyazaki T, Yamazaki T, Nakamura D, et al. Surgery or stereotactic body radiotherapy for elderly stage Ⅰ lung cancer? A propensity score matching analysis［J］. Surg Today, 2017, 47(12): 1476-1483. DOI: 10.1007/s00595-017-1536-4. ［5］ Rosen JE, Salazar MC, Wang Z, et al. Lobectomy versus stereotactic body radiotherapy in healthy patients with stage Ⅰ lung cancer［J］. J Thorac Cardiovasc Surg, 2016, 152(1): 44-54, e9. DOI: 10.1016/j.jtcvs.2016.03.060. ［6］ Aoki M, Hatayama Y, Kawaguchi H, et al. Clinical outcome of stereotactic body radiotherapy for primary and oligometastatic lung tumors: a single institutional study with almost uniform dose with different five treatment schedules［J］. Radiat Oncol, 2016, 11: 5. DOI: 10.1186/s13014-016-0581-2. ［7］ Grills IS, Hope AJ, Guckenberger M, et al. A collaborative analysis of stereotactic lung radiotherapy outcomes for earlystage nonsmallcell lung cancer using daily online conebeam computed tomography imageguided radiotherapy［J］. J Thorac Oncol, 2012, 7(9): 1382-1393. DOI: 10.1097/JTO.0b013e318260e00d. ［8］ Chang JY, Li QQ, Xu QY, et al. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of nonsmall cell lung cancer: how to fly in a "no fly zone"［J］. Int J Radiat Oncol Biol Phys, 2014, 88(5): 1120-1128. DOI: 10.1016/j.ijrobp.2014.01.022. ［9］ Chaudhuri AA, Tang C, Binkley MS, et al. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultracentral lung tumors［J］. Lung Cancer, 2015, 89(1): 50-56. DOI: 10.1016/j.lungcan.2015.04.014. ［10］ Haseltine JM, Rimner A, Gelblum DY, et al. Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree［J］. Pract Radiat Oncol, 2016, 6(2): e27e33. DOI: 10.1016/j.prro.2015.09.012. ［11］ Bezjak A, Paulus R, Gaspar LE, et al. Efficacy and toxicity analysis of NRG Oncology/RTOG 0813 trial of stereotactic body radiation therapy (SBRT) for centrally located nonsmall cell lung cancer (NSCLC)［J］. Int J Radiat Oncol Biol Phys, 2016, 96 Suppl 2: S8. ［12］ Senthi S, Haasbeek CJ, Slotman BJ, et al. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review［J］. Radiother Oncol, 2013, 106(3): 276-282. DOI: 10.1016/j.radonc.2013.01.004. ［13］ Tekatli H, Senan S, Dahele M, et al. Stereotactic ablative radiotherapy (SABR) for central lung tumors: plan quality and longterm clinical outcomes［J］. Radiother Oncol, 2015, 117(1): 64-70. DOI: 10.1016/j.radonc.2015.09.028. ［14］ Bezjak A, PaulusR, Gaspar LE, et al. Primary study endpoint analysis for NRG Oncology/RTOG 0813 trial of stereotactic body radiation therapy (SBRT) for centrally located nonsmall cell lung cancer (NSCLC)［J］. Int J Radiat Oncol Biol Phys, 2016, 94(1): 5-6. ［15］ Ghaye B, Wanet M, EI Hajjam M. Imaging after radiation therapy of thoracic tumors［J］. Diagn Interv Imaging, 2016, 97(10): 1037-1052. DOI: 10.1016/j.diii.2016.06.019. ［16］ Faruqi S, Giuliani ME, Raziee H, et al. Interrater reliability of the categorizationof late radiographic changes after lung stereotactic body radiation therapy［J］. Int J Radiat Oncol Biol Phys, 2014, 89(5): 1076-1083. DOI: 10.1016/j.ijrobp.2014.04.042. ［17］ Peulen H, Mantel F, Guckenberger M, et al. Validation of highrisk computed tomography features for detection of local recurrence after stereotactic body radiation therapy for earlystage nonsmall cell lung cancer［J］. Int J Radiat Oncol Biol Phys, 2016, 96(1): 134-141. DOI: 10.1016/j.ijrobp.2016.04.003. ［18］ Huang K, Senthi S, Palma DA, et al. Highrisk CT features for detection of local recurrence after stereotacticablative radiotherapy for lung cancer［J］. Radiother Oncol, 2013, 109(1): 51-57. DOI: 10.1016/j.radonc.2013.06.047. ［19］ Louie AV, Senan S, Dahele M, et al. Stereotactic ablative radiation therapy for subcentimeter lung tumors: clinical, dosimetric, and image guidance considerations［J］. Int J Radiat Oncol Biol Phys, 2014, 90(4): 843-849. DOI: 10.1016/j.ijrobp.2014.06.064. ［20］ Ricardi U, Frezza G, Filippi AR, et al. Stereotactic ablative radiotherapy for stage Ⅰ histologically proven nonsmall cell lung cancer: an Italian multicenter observational study［J］. Lung Cancer, 2014, 84(3): 248-253. DOI: 10.1016/j.lungcan.2014.02.015. ［21］ Loganadane G, Martinetti F, Mercier O, et al. Stereotactic ablative radiotherapy for early stage nonsmall cell lung cancer: a critical literature review of predictive factors of relapse［J］. Cancer Treat Rev, 2016, 50: 240-246. DOI: 10.1016/j.ctrv.2016.10.002. ［22］ Woody NM, Stephans KL, Marwaha G, et al. Stereotactic body radiation therapy for nonsmall cell lung cancer tumors greater than 5cm: safety and efficacy［J］. Int J Radiat Oncol Biol Phys, 2015, 92(2): 325-331. DOI: 10.1016/j.ijrobp.2015.01.045. ［23］ Marwaha G, Stephans KL, Woody NM, et al. Lung stereotactic body radiation therapy: regional nodal failure is not predicted by tumor size［J］. J Thorac Oncol, 2014, 9(11): 1693-1697. DOI: 10.1097/JTO.0000000000000313. ［24］ Kohutek ZA, Wu AJ, Zhang Z, et al. FDGPET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for nonsmall cell lung cancer［J］. Lung Cancer, 2015, 89(2): 115-120. DOI: 10.1016/j.lungcan.2015.05.019. ［25］ Leeman JE, Rimner A, Montecalvo J, et al. Histologic subtype in core lung biopsies of earlystage lung adenocarcinoma is a prognostic factor for treatment response and failure patterns after stereotactic body radiation therapy［J］. Int J Radiat Oncol Biol Phys, 2017, 97(1): 138-145. DOI: 10.1016/j.ijrobp.2016.09.037.

[1]	Li Ping, Sun Xiaonan. Application of the combination of stereotactic body radiation therapy and immune checkpoint inhibitors in non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(2): 116-120.
[2]	Zhang Lili, Yu Yonghua. Research progress of stereotactic body radiation therapy for lung oligometastases of colorectal cancer [J]. Journal of International Oncology, 2020, 47(10): 630-633.
[3]	Cai Liang, Shen Yali. Application of stereotactic body radiation therapy in advanced renal cell carcinoma [J]. Journal of International Oncology, 2019, 46(10): 627-630.
[4]	Chen-Ya-Ping, JIANG Xiao-Xiao, JIANG Guan, FENG Shou-Xin. A Metaanalysis of transcatheter arterial chemoembolization comparing stereotactic body radiation therapy in patients for primary hepatic carcinoma [J]. Journal of International Oncology, 2015, 42(3): 182-187.
[5]	Lin Li, Zhou Fuxiang. Stereotactic body radiotherapy for early stage nonsmall cell lung cancer [J]. Journal of International Oncology, 2015, 42(10): 773-775.
[6]	LIN Gang, WANG Zhun, XU Ya-Ping. Application of stereotactic body radiotherapy in extracranial metastases [J]. Journal of International Oncology, 2014, 41(11): 820-823.